These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1139 related items for PubMed ID: 29661141

  • 1. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M, Domagala P, Miszewska-Szyszkowska D, Sitarek E, Jozwik A, Kwiatkowski A, Durlik M.
    BMC Infect Dis; 2018 Apr 16; 18(1):179. PubMed ID: 29661141
    [Abstract] [Full Text] [Related]

  • 2. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N, Winston DJ, Razonable RR, Lyon GM, Silveira FP, Wagener MM, Stevens-Ayers T, Edmison B, Boeckh M, Limaye AP.
    JAMA; 2020 Apr 14; 323(14):1378-1387. PubMed ID: 32286644
    [Abstract] [Full Text] [Related]

  • 3. Monitoring of Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity in Heart Transplant Recipients: Clinical Utility of the QuantiFERON-CMV Assay for Management of Posttransplant CMV Infection.
    Chiereghin A, Potena L, Borgese L, Gibertoni D, Squarzoni D, Turello G, Petrisli E, Piccirilli G, Gabrielli L, Grigioni F, Lazzarotto T.
    J Clin Microbiol; 2018 Apr 14; 56(4):. PubMed ID: 29305542
    [Abstract] [Full Text] [Related]

  • 4. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O.
    Transplantation; 2011 Jan 27; 91(2):251-5. PubMed ID: 21099744
    [Abstract] [Full Text] [Related]

  • 5. QuantiFERON-Cytomegalovirus Assay for Prediction of Cytomegalovirus Viremia in Kidney Transplant Recipients: Study From High Cytomegalovirus Seroprevalence Country.
    Pongsakornkullachart K, Chayakulkeeree M, Vongwiwatana A, Kantakamalakul W, Skulratanasak P, Phoompoung P.
    Front Cell Infect Microbiol; 2022 Jan 27; 12():893232. PubMed ID: 35646728
    [Abstract] [Full Text] [Related]

  • 6. Real-world experience of Quantiferon-CMV directed prophylaxis in lung transplant recipients.
    Gardiner BJ, Lee SJ, Robertson AN, Cristiano Y, Snell GI, Morrissey CO, Peleg AY, Westall GP.
    J Heart Lung Transplant; 2022 Sep 27; 41(9):1258-1267. PubMed ID: 35868965
    [Abstract] [Full Text] [Related]

  • 7. Expanded valganciclovir prophylaxis in kidney transplant recipients is associated with lower incidence of cytomegalovirus infection.
    Večerić-Haler Ž, Bizjak B, Romozi K, Arnol M.
    Clin Nephrol; 2022 Sep 27; 88(13):126-130. PubMed ID: 28601128
    [Abstract] [Full Text] [Related]

  • 8. Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation.
    Noble J, Gatault P, Sautenet B, Gaudy-Graffin C, Beby-Defaux A, Thierry A, Essig M, Halimi JM, Munteanu E, Alain S, Buchler M.
    J Clin Virol; 2018 Sep 27; 99-100():38-43. PubMed ID: 29306112
    [Abstract] [Full Text] [Related]

  • 9. CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor.
    Schachtner T, Stein M, Reinke P.
    Transplantation; 2017 Oct 27; 101(10):e315-e325. PubMed ID: 28594749
    [Abstract] [Full Text] [Related]

  • 10. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
    Lautenschlager I, Loginov R, Mäkisalo H, Höckerstedt K.
    J Clin Virol; 2015 Oct 27; 71():73-5. PubMed ID: 26318605
    [Abstract] [Full Text] [Related]

  • 11. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis.
    Boudreault AA, Xie H, Rakita RM, Scott JD, Davis CL, Boeckh M, Limaye AP.
    Transpl Infect Dis; 2011 Jun 27; 13(3):244-9. PubMed ID: 21414119
    [Abstract] [Full Text] [Related]

  • 12. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D, Saldan A, Fiscon M, Cofano S, Paciolla A, Furian L, Ekser B, Biasolo MA, Cusinato R, Mengoli C, Bonfante L, Rossi B, Rigotti P, Sgarabotto D, Barzon L, Palù G.
    J Infect Dis; 2010 Aug 15; 202(4):585-94. PubMed ID: 20594105
    [Abstract] [Full Text] [Related]

  • 14. Extended Low-Dose Valganciclovir Is Effective Prophylaxis Against Cytomegalovirus in High-Risk Kidney Transplant Recipients With Near-Complete Eradication of Late-Onset Disease.
    Fayek SA, Beshears E, Lieber R, Alvey N, Sauer A, Poirier J, Hollinger EF, Olaitan OK, Jensik S, Geyston J, Brokhof MM, Hodowanec AC, Hertl M, Simon DM.
    Transplant Proc; 2016 Aug 15; 48(6):2056-2064.e1. PubMed ID: 27569944
    [Abstract] [Full Text] [Related]

  • 15. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
    Kuo HT, Ye X, Sampaio MS, Reddy P, Bunnapradist S.
    Transplantation; 2010 Nov 27; 90(10):1091-8. PubMed ID: 20885340
    [Abstract] [Full Text] [Related]

  • 16. Clinical utility of a cytomegalovirus-specific T cell assay in assessing the risk of post-prophylaxis cytomegalovirus infection and post-treatment relapse.
    Dioverti MV, Bhaimia E, Yetmar ZA, Melendez DP, Misner L, Beito E, Deziel PJ, Theel ES, Razonable RR.
    Clin Transplant; 2023 Dec 27; 37(12):e15143. PubMed ID: 37805968
    [Abstract] [Full Text] [Related]

  • 17. A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients.
    Reischig T, Vlas T, Kacer M, Pivovarcikova K, Lysak D, Nemcova J, Drenko P, Machova J, Bouda M, Sedivcova M, Kormunda S.
    J Am Soc Nephrol; 2023 May 01; 34(5):920-934. PubMed ID: 36749127
    [Abstract] [Full Text] [Related]

  • 18. Tailoring cytomegalovirus prophylaxis based on T cell immunity panel assessment in kidney transplant patients at high risk of cytomegalovirus.
    Servais AM, McMullen JS, Bowen R, Kleiboeker SB, Ulloa I, Duncan K, Miles CD.
    Transpl Infect Dis; 2024 Aug 01; 26(4):e14291. PubMed ID: 38708965
    [Abstract] [Full Text] [Related]

  • 19. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
    McKeen JT, Tsapepas DS, Li H, Anamisis A, Martin ST.
    Prog Transplant; 2015 Mar 01; 25(1):39-44. PubMed ID: 25758799
    [Abstract] [Full Text] [Related]

  • 20. Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients Is Associated with Protracted Cold Ischemic Time of Seropositive Donor Organs.
    Schlott F, Steubl D, Hoffmann D, Matevossian E, Lutz J, Heemann U, Hösel V, Busch DH, Renders L, Neuenhahn M.
    PLoS One; 2017 Mar 01; 12(1):e0171035. PubMed ID: 28129395
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.